FDA Staff Raises Concerns on Two Cancer Drug Applications

(MedPage Today) -- For the first time since last July the FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Thursday to evaluate two cancer drugs after FDA staff voiced concerns about benefit-risk assessments, despite positive trial...
Source
MedPage Today
Opens original article in a new tab



